If you made any changes in Pure these will be visible here soon.

Personal profile


Dr. Cathy Xie is a research fellow at the Australian Translational Medicinal Chemistry Facility (ATMCF) in Monash Institute of Pharmaceutical Sciences (MIPS). Her current project is in partnership with the Australian largest radiopharmaceutical company - Cyclotek, aiming at developing novel 18F-labelled radiotracers for PET imaging, as new and better diagnostics of various human cancers with potential in clinic application.

Cathy has a long-term research focus on drug discovery. She received her doctorate degree in Medicinal Chemistry from Monash University in 2020. Her PhD project is about developing novel GSTO1-1 inhibitors for the treatment of inflammatory conditions.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Education/Academic qualification

Medicinal Chemistry, Doctor of Philosophy, Development of GSTO1-1 inhibitors for the treatment of inflammatory conditions, MONASH UNIVERSITY

30 Sept 20162 Apr 2020

Award Date: 2 Apr 2020

Pharmaceutical Sciences, Bachelor of Science, China Pharmaceutical University

1 Sept 201230 Jun 2016

Award Date: 30 Jun 2016

Research area keywords

  • Drug Discovery
  • Medicinal Chemistry
  • Chemical Biology
  • Drug Development

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or